05.21.25 -- Partners To Support Your Biologic API & Drug Product Projects

Leverage robust development strategies and enable an optimized process for mAb development and manufacturing, efficiency and speed with exceptional quality, and high titers with lower-cost workflows for maximum ROI.

Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.

INCOG BioPharma's Director of Technical Transfer, JoAnne Jacobs, details the roots behind our team and our purpose: to deliver best-in-class CDMO services to help fulfill the world's increasing need for injectable drug product supply.

We are a European biotechnological company that specializes in the production of sterile biotechnological products in a manufacturing plant that meets GMP requirements.

Detra Glinatsis, Vice President of Business Development, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.

Lifecore’s experts have gained the know-how to build processes around your requirements for smooth scale-up and high-quality manufacturing, whether we’re your primary partner or a secondary source for manufacturing.

The ability to administer high doses of biologics subcutaneously offers numerous benefits, including reduced treatment burden, improved patient convenience, and increased adherence.

Performing the transfer of a product or technology from a small-scale development process to full-scale commercial manufacturing can be difficult, but vetting for the right CMO partner can pose its own unique challenges.

Discover a partner with extensive expertise and flexible solutions across clinical phases and commercialization for mAbs, bispecific antibodies, fusion proteins, and antibody fragments.

Kymanox provides turnkey services to bring your product from concept to commercialization — and helps keep your product on the market. Kymanox has expertise in injectables, respiratory combination products, and in ocular products.

We continuously strive to advance cutting-edge biopharmaceutical manufacturing while fostering long-term partnerships built on trust and transparency.